What is Catalent?
Catalent operates as a premier Contract Development and Manufacturing Organization (CDMO), providing comprehensive services that span product development, launch, and full life-cycle supply for pharmaceutical, biotechnology, and consumer health industries. The company leverages extensive expertise in development sciences, delivery technologies, and multi-modality manufacturing to support personalized medicines, blockbuster drugs, and consumer health brand extensions. Its broad capabilities position it as a critical partner for companies seeking to bring innovative therapies and products to patients worldwide.
How much funding has Catalent raised?
Catalent has raised a total of $5.2B across 9 funding rounds:
Stock Offering
$870M
Debt
$410.1M
Stock Offering
$24.2M
Debt
$450M
Stock Offering
$387M
Debt
$1.2B
Debt
$500M
Stock Offering
$500M
Debt
$903.4M
Stock Issuance/Offering (2014): $870M with participation from Undisclosed
Debt (2016): $410.1M led by Undisclosed
Stock Issuance/Offering (2017): $24.2M supported by RBC Capital Markets, Morgan Stanley, JPMorgan Chase, and BofA Merrill Lynch
Debt (2017): $450M featuring Undisclosed
Stock Issuance/Offering (2018): $387M backed by Morgan Stanley, RBC Capital Markets, Wells Fargo Securities, JPMorgan Chase, and BofA Merrill Lynch
Debt (2019): $1.2B with participation from JPMorgan Chase Bank
Debt (2019): $500M led by Undisclosed
Stock Issuance/Offering (2020): $500M supported by JPMorgan Chase and UBS Investment Bank
Debt (2020): $903.4M featuring Undisclosed
Key Investors in Catalent
Morgan Stanley
Morgan Stanley is a leading global financial services firm providing investment banking, securities, wealth management, and investment management services. Their involvement suggests a focus on large-scale corporate finance and capital markets activities.
JPMorgan Chase
JPMorgan Chase is a major global financial services firm offering a wide array of banking and investment services. Their participation indicates significant backing for Catalent's strategic initiatives and operational scaling.
Wells Fargo Securities
Wells Fargo Securities is the investment banking and capital markets division of Wells Fargo, providing a broad range of financial services. Their engagement points to Catalent's access to substantial debt and equity financing.
What's next for Catalent?
With substantial enterprise-level capital and recent strategic investments, Catalent is well-positioned for continued expansion and innovation. The company's focus on advanced development sciences and manufacturing technologies suggests a strategic direction towards enhancing its capacity for complex biologics, gene therapies, and other cutting-edge treatments. Future growth is likely to involve further integration of its service offerings, potential acquisitions to broaden its technological portfolio, and expansion of its global manufacturing footprint to meet increasing demand from its diverse client base. This sustained financial backing indicates a trajectory aimed at solidifying its leadership in the CDMO market and addressing evolving healthcare needs.
See full Catalent company page
